| 标题 |
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet. Respiratory medicine 作者:Wang Z; Cheng Y; An T; Gao H; Wang K; et al 出版日期:2018/09/01 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)